drugset
drugset / Trial / NCT07061288

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCT07061288 ↗

Phase 1 Recruiting 116 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

Timeline

Start
2025-09-03
Primary completion
2027-06-21
Completion
2027-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule — —

Indications

schizophrenia